Syndax Pharmaceutica
SNDX
Delayed Nasdaq - 08/17 10:00:00 pm
7.18USD
-1.24%
Prev.7.2700
Open7.2300
High7.2544
Low6.8400
Volume165 294
Financials
Sales 2018 1,58 M
EBIT 2018 -81,0 M
R. net 2018 -78,6 M
Tréso. 2018 152 M
Rend. 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 10,0x
EV / Sales 2019 0,00x
Capitalization 168 M
Company
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer therapies.Its products include candidate and entinostat.The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October...
Sector :
Biopharmaceuticals
Calendar :
2018-11-07 Earnings Release
Trading Rating :
Investor Rating :
Latest news
08/14SYNDAX PHARMACEUTICALS : Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
AQ
08/08SYNDAX PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/07SYNDAX : 2Q Earnings Snapshot
AQ
08/07SYNDAX PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
08/03SYNDAX PHARMACEUTICALS : to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
AQ
07/31SYNDAX PHARMACEUTICALS : to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
PR
06/25Roche taps gRED's Sabry as global head of partnering
AQ
06/20SYNDAX PHARMACEUTICALS INC : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishBearish
Resistance7,499,129,48
Spread/Res.-4,1%-21%-24%
Spread/Supp.13%13%13%
Support6,336,336,33